STOCK TITAN

HUTCHMED wins China approval for SYVIK in two diseases

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

HUTCHMED (China) Limited announced China NMPA approval of SYVIK (sovleplenib) for primary ITP and warm antibody autoimmune hemolytic anemia (wAIHA), its first in-house discovered immunology drug approved for commercialization. In Phase III ESLIM-01, involving 188 adults with ITP, durable response was 48.4% with SYVIK versus zero with placebo (p<0.0001); overall response was 68.3% versus 14.5% through weeks 0–12 and 70.6% versus 16.1% through weeks 0–24 (both p<0.0001).

For wAIHA, Phase III ESLIM-02 results showed durable response during weeks 5–24 of 66% versus 15% and overall response of 70% versus 22% (both p<0.0001). HUTCHMED also reported preclinical HMPL-A830 activity across 55 KRAS-altered tumor cell lines and in mouse tumor models; the candidate is being evaluated in Phase Ia of a global Phase I trial. In September 2026, subsidiary HUTCHMED Limited granted a GSK subsidiary worldwide rights outside Mainland China, Hong Kong, Macau and Taiwan; HUTCHMED Limited is responsible for global Phase I development, and the GSK subsidiary for subsequent development and commercialization outside those territories.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Major pointSYVIK received China NMPA approvals for two autoimmune indications.

Negative

  • None.
ESLIM-01 participants 188 adults ITP Phase III trial; participants had received at least one prior line of standard therapy
ITP durable response 48.4% vs zero SYVIK vs placebo in ESLIM-01
ITP overall response, weeks 0–12 68.3% vs 14.5% SYVIK vs placebo in ESLIM-01
ITP overall response, weeks 0–24 70.6% vs 16.1% SYVIK vs placebo in ESLIM-01
wAIHA durable response 66% vs 15% During weeks 5–24 in ESLIM-02; SYVIK vs placebo
wAIHA overall response 70% vs 22% ESLIM-02; SYVIK vs placebo
Tumor cell lines tested 55 cell lines In vitro profiling of HMPL-A830 across tumor cell lines with diverse KRAS alterations
Antibody-Targeted Therapy Conjugate technical
"a first-in-class Antibody-Targeted Therapy Conjugate"
An antibody-targeted therapy conjugate is a medicine made by attaching a disease-seeking antibody to a small therapeutic payload, so the antibody guides the drug directly to specific cells (like a guided delivery truck dropping medicine at one house). It matters to investors because this design can increase effectiveness and reduce side effects compared with untargeted treatments, but also adds development, manufacturing and regulatory complexity that can affect cost, approval risk and commercial potential.
pan-KRAS technical
"its pan-KRAS payload exhibits a dual-action mechanism"
Pan-KRAS describes a drug or therapeutic approach designed to work against many different mutations of the KRAS gene rather than a single specific variant. For investors, a pan-KRAS treatment is important because it can address a larger group of patients—like a universal key that fits many locks—potentially increasing the market opportunity and clinical value, while also carrying development and regulatory risks tied to demonstrating safety and broad effectiveness.
durable response rate medical
"durable response rate of 48.4% compared to zero with placebo"
Orphan Drug Designation regulatory
"granted Orphan Drug Designation by the US FDA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
drug-to-antibody ratio technical
"a stable drug-to-antibody ratio (DAR)"
Drug-to-antibody ratio is the average number of small drug molecules attached to each antibody in an antibody-drug conjugate, a targeted cancer treatment. It matters to investors because this number affects how potent, stable and safe the medicine is, as well as how consistently it can be manufactured; think of it like the number of batteries in a flashlight — more can mean brighter effect but also more weight, complexity and risk.
Phase Ia medical
"The Phase Ia part of an ongoing global Phase I trial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which conditions did HUTCHMED's SYVIK get approved for in China?

SYVIK (sovleplenib) was approved in China for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia. HUTCHMED described it as its first in-house discovered immunology drug approved for commercialization.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​


​

FORM 6-K

​


​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

For the Month of November 2026

​

Commission File Number: 001-37710

​


​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​


​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​


​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​


​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.

  ​ ​ ​

Description

​

​

​

Exhibit 99.1

​

Press release relating to HUTCHMED highlights HMPL-A830 pre-clinical data presented at the 38th EORTC-NCI-AACR International Conference on molecular targets and cancer therapeutics

​

​

​

Exhibit 99.2

​

Press release relating to HUTCHMED announces China NMPA approval of SYVIK® (sovleplenib) for the treatment of primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia

2


​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ Johnny Cheng

​

Name:

Johnny Cheng

​

Title:

Chief Financial Officer

​

​

Date: November 19, 2026

3


Exhibit 99.1

​

Graphic

​

Press Release

​

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

​

— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —

​

— Broad-spectrum activity across multiple KRAS mutations, combining inhibition of both ON and OFF states to intercept adaptive resistance —

​

Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 19, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A830 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held on November 18–20, 2026, in Barcelona, Spain. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent KRAS small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (“EGFR”) antibody.

​

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. While recent targeted therapies have validated KRAS (the most dominant RAS isoform) as a viable therapeutic target, significant clinical gaps remain, including safety limitations and disease progression driven by acquired resistance, often mediated by upstream receptor tyrosine kinase upregulation. HMPL-A830 is designed to address this unmet need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.

​

In vitro profiling demonstrated that its pan-KRAS payload exhibits a dual-action mechanism, simultaneously blocking both KRAS “ON” (GTP-RAF1 binding) and “OFF” (GDP-to-GTP exchange) activities. Potent antiproliferative activity was observed across a broad panel of 55 tumor cell lines harboring diverse KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as wild-type amplification. HMPL-A830 exhibited high binding affinity and rapid internalization into EGFR-positive cells. It also demonstrated a strong bystander killing effect, effectively eliminating neighboring EGFR-negative tumor cells, while maintaining robust antibody-dependent cellular cytotoxicity (ADCC) activity.

​

In mouse models, HMPL-A830 showed dose-dependent and robust antitumor efficacy across various EGFR-positive tumor models harboring KRAS alterations. HMPL-A830 achieved more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor (administered alone or in combination with cetuximab), and a TROP2-targeted Topo I-inhibitor antibody-drug conjugate. Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed a stronger and more sustained inhibition of EGFR/KRAS downstream signaling than the naked antibody, alongside a stable drug-to-antibody ratio (DAR) maintained in mouse, monkey, and human plasma.

​

In September 2026, HUTCHMED Limited (a subsidiary of the Company) entered into an exclusive development and license agreement with a subsidiary of GSK plc (“GSK”), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan. 

​

The Phase Ia part of an ongoing global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).

​


About HUTCHMED ATTCs

HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.

 

Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.

 

About KRAS

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer (“CRC”), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma (“PDAC”) patients.1 KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.

 

While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.

 

About EGFR

EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer (“NSCLC”). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including, without limitation, statements concerning HUTCHMED’s future plans and prospects, its expectations regarding the therapeutic potential of HMPL-A830 and other drug candidates from the ATTC platform and the further development of HMPL-A830 and other drug candidates from the ATTC platform in this and other indications, as well as the safety, efficacy, tolerability, scalability or combinability of all candidates from the ATTC platform. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the considerations; satisfaction of the conditions precedent to the consummation of the proposed transactions (including the ability of the parties to secure regulatory approvals on the terms expected, at all or in a timely manner); the ability of the parties to complete the proposed transactions; the continued sufficiency of preclinical and clinical data to support development and approval of the ATTC-based R&D candidates in China, the United States and other jurisdictions; their potential to gain clinical trial approvals from regulatory authorities; the efficacy and safety profile of HMPL-A830 and other drug candidates from the ATTC platform; the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of HMPL-A830 and other drug candidates from the ATTC platform in China, the United States or other jurisdictions; its potential to gain approvals from regulatory authorities on an expedited basis or at all; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC candidates; HUTCHMED or GSK’s ability to fund, implement and complete its further clinical development and commercialization plans for HMPL-A830 and other drug candidates from the ATTC platform and the timing of these events. In addition, when or if used herein, the words and phrases “aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “on track,” “predicts,” “plans,” “potential,” “promising,” “should,” “to be,” “will,” and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

​

​

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Deutsche Numis

Joint Broker

Freddie Barnfield / Jeffrey Wong / Duncan Monteith

+44 20 7260 1000

​

​

__________________________

REFERENCES

1  Singhal A, Li BT & O’Reilly EM. Targeting KRAS in cancer. Nat Med 30, 969–983 (2024). DOI: 10.1038/s41591-024-02903-0


Exhibit 99.2

​

Graphic

​

Press Release

​

HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and
Warm Antibody Autoimmune Hemolytic Anemia

​

— SYVIK® becomes the first novel Syk inhibitor approved in China — 

— Simultaneous approvals in two underserved autoimmune indications supported by positive ESLIM-01 trial in ITP and ESLIM-02 trial in wAIHA —

— Expands HUTCHMED’s commercial portfolio into immunology, establishing a new presence beyond oncology — 

Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 19, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the China National Medical Products Administration (“NMPA”) has granted simultaneous approval for two New Drug Applications (NDAs) of SYVIK® (sovleplenib), a novel, selective oral small molecule inhibitor targeting spleen tyrosine kinase (“Syk”):

​

●Immune Thrombocytopenia (“ITP”): For the treatment of adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy; and
●Warm Antibody Autoimmune Hemolytic Anemia (“wAIHA”): For the treatment of adult patients with wAIHA who have had an insufficient response to prior corticosteroid therapy.

The approval for ITP is supported by data from ESLIM-01 (NCT05029635), a randomized, double-blinded, placebo-controlled Phase III trial in China of SYVIK® in 188 adult patients who had received at least one prior line of standard therapy. Results from ESLIM-01 study were published in The Lancet Haematology. SYVIK® demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP compared to placebo, with durable response rate of 48.4% compared to zero with placebo (p<0.0001). Overall response rates were 68.3% at 0–12 weeks and 70.6% at 0–24 weeks with SYVIK®, compared to 14.5% and 16.1% with placebo (p<0.0001). SYVIK® demonstrated a tolerable safety profile and improvement in quality of life. 

​

The approval for wAIHA is supported by data from ESLIM-02 (NCT05535933), a randomized, double-blind, placebo-controlled Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to prior glucocorticoid treatment. Results from the Phase II part of ESLIM-02 were published in The Lancet Haematology. Results from the Phase III part were presented at the European Hematology Association (“EHA”) 2026 Congress. SYVIK® demonstrated a significantly higher durable response rate during weeks 5–24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, SYVIK® demonstrated superior efficacy across several key metrics; specifically, the overall response rate — defined as hemoglobin ≥100 g/L with an increase of ≥20 g/L from baseline without rescue therapy — was significantly increased (70% vs 22%, p<0.0001). SYVIK® demonstrated a favorable safety profile with no treatment-related deaths or discontinuations in the SYVIK® group.

​

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “The simultaneous approvals of SYVIK® for both ITP and wAIHA represent a significant milestone for HUTCHMED as our first in-house discovered immunology drug approved for commercialization. Patients with these chronic autoimmune blood conditions often face disease relapses and tolerability challenges associated with prolonged standard treatments. SYVIK® has demonstrated clinically meaningful efficacy, rapid onset, and sustained durable responses with a favorable safety profile across the pivotal ESLIM-01 and ESLIM-02 studies. We are committed to making this new targeted treatment option accessible to patients across China, addressing critical unmet needs and helping patients better manage these challenging conditions.”

​


In addition to the regulatory approvals in China, sovleplenib was granted Orphan Drug Designation by the US FDA for the treatment of primary ITP and autoimmune hemolytic anemia in October 2026. This designation underscores the clinical value of sovleplenib and its potential to address significant unmet medical needs on a global scale. HUTCHMED retains full worldwide rights to sovleplenib and continues to evaluate strategic pathways to support its global development.

​

About ITP

ITP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising.1 ITP is also associated with fatigue (reported in up to 39% of adults with ITP) and impaired quality of life.2,3,4,5,6 The incidence of primary ITP in adults is 3.3/100,000 adults per year with a prevalence of 9.5 per 100,000 adults.7 Based on this prevalence rate, approximately 110,000 patients are estimated to be living with primary ITP in China, in addition to 56,000 patients in the US, Germany, France, Italy, Spain, UK, and Japan. It has been estimated that as many as 145,000 patients are living with chronic ITP in major pharmaceutical markets excluding China.8

​

Adult ITP is a heterogeneous disease that can persist for years, even with best available care, and treatments are infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse.9 Thus, there remains a significant population of patients who have limited sensitivity to currently available agents and are in need of new treatments.

​

As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition represents a promising approach to management of ITP.10

​

About wAIHA

Autoimmune hemolytic anemia (“AIHA”) is an autoimmune disorder characterized by the destruction of red blood cells (“RBCs”) due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8-11%.11,12 wAIHA is the most common form of AIHA,13 accounting for about 75-80% of all adult AIHA cases.14

​

The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (FcγR) bearing macrophages is thought to be the pathogenic mechanism in wAIHA.15 Activated Syk mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs.16 In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells.17 Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production.

​

About SYVIK®

SYVIK® (sovleplenib) is a novel, selective inhibitor of Syk. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

​

HUTCHMED currently retains all rights to sovleplenib worldwide. 

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first five medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​

​

​

​

​

​


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of sovleplenib, the further clinical development for sovleplenib, its expectations as to whether any studies on sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of sovleplenib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in other jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of sovleplenib for a targeted indication; and HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for sovleplenib, and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

​

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

​

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Deutsche Numis

Joint Broker

Duncan Monteith / Ramin Naji

+44 20 7545 8000

​

____________________

REFERENCES

1 Zufferey A, et al. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6(2), 16.

2 McMillan R, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb;83(2):150-4.

3 Snyder CF, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008 Oct;24(10):2767-76.

4 Doobaree IU, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016 Oct;97(4):321-30.

5 Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010 Jul;95(7):1167-75.

6 Sarpatwari A, et al. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol. 2010 Oct;151(2):189-91.

7 Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.

8 Clarivate Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018.

9 Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.

10 Crowley MT, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages. J. Exp. Med. 186(7), 1027–1039 (1997).

11 Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29 (1):1-9. doi: 10.1016/j.jaut.2007.05.002.

12 Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89 (9):E150-5. doi: 10.1002/ajh.23767.

13 Cotran Ramzi S, Kumar Vinay, Fausto Nelson, Nelso Fausto, Robbins Stanley L, Abbas Abul K. Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders; 2005. p. 637.

14 Gehrs BC, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002; 69:258–271. doi: 10.1002/ajh.10062.

15 Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010; 24(3):195‐210. doi: 10.1016/j.tmrv.2010.03.002.

16 Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018; 14(10):857‐872. doi: 10.1080/1744666x.2018.1521722.

17 Davidzohn N, Biram A, Stoler‐Barak L, Grenov A, Dassa B, Shulman Z. SYK degradation restrains plasma cell formation and promotes zonal transitions in germinal centers. J Exp Med. 2020; 217(3):e20191043. doi: 10.1084/jem.20191043.


Filing Exhibits & Attachments

2 documents

Keep reading